News

GSK’s pazopanib hits endpoint
Enlarge image

BusinessUK

GSK’s pazopanib hits endpoint

03.06.2013 - GlaxoSmithKline’s multi kinase blocker pazopanib has increased progression free survival in women with advanced ovarian cancer by 5.6 months.

At the ASCO meeting, the British drug major reported that the median time to disease progression under the VEGFR, PDGFR, c-KIT blocker post-surgery and chemotherapy was 17.9 months, compared with 12.3 months in patients receiving placebo. GSK announced that it will file an MAA in the US for pazopanib as first-in-class maintenance therapy after surgery and chemotherapy. In contrast to Europe where Roche’s bevacizumab is approved as maintenance therapy, there is no comparable treatment approved by the FDA. 

91% of the 940 patients with advanced epithelial ovarian cancer had stage III/IV disease at diagnosis and no residual disease following surgery. While efficacy was shown, more serious adverse drug effects were observed in the pazopanib group (26%) than in the placebo arm (11%) of the study. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/gsks-pazopanib-hits-endpoint.html

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.

R&DNetherlandsSpainAustria

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

Events

All Events

Current issue

All issues

Product of the week

Products